Genprex to Present at Biotech Showcase™ 2020 in San Francisco
January 06 2020 - 8:00AM
Business Wire
Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a
clinical-stage gene therapy company utilizing a unique, nonviral
proprietary platform designed to deliver tumor suppressor genes to
cancer cells, today announced it will attend and present at the
Biotech Showcase™ 2020 to be held January 13–15, 2020 at the Hilton
San Francisco Union Square in San Francisco.
Genprex’s President and Chief Operating Officer, Julien Pham,
MD, MPH, will lead the Company’s presentation and, along with
Rodney Varner, the Company’s Chief Executive Officer, will be
available for one-on-one investor meetings.
Genprex will present at the Biotech Showcase 2020 as
follows:
Date: Monday, January 13, 2020
Time: 11:30 a.m. PT (2:30 p.m. ET) Track: Yosemite C
(Ballroom Level) Location: Hilton San Francisco Union Square
Hotel, 333 O'Farrell Street, San Francisco
Biotech Showcase, produced by Demy-Colton and EBD Group, is an
investor conference focused on driving advances in therapeutic
development by providing a sophisticated networking platform for
executives and investors that fosters investment and partnership
opportunities. The conference takes place each year during the
course of one of the industry's largest gatherings and busiest
weeks.
“We are delighted that Genprex will be presenting at Biotech
Showcase this year,” said Sara Demy, CEO of Demy-Colton. “Biotech
Showcase is a prime occasion for life science entrepreneurs and
investors to come together to discover the potential of innovative
technologies that will drive the future of drug discovery.”
About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company
developing potentially life-changing technologies for cancer
patients based upon a unique proprietary technology platform.
Genprex’s platform technologies are designed to administer
cancer-fighting genes by encapsulating them into nanoscale hollow
spheres called nanovesicles, which are then administered
intravenously and taken up by tumor cells where they express
proteins that are missing or found in low quantities. The company’s
lead product candidate, Oncoprex™ immunogene therapy for non-small
cell lung cancer (NSCLC), has a multimodal mechanism of action
whereby it interrupts cell signaling pathways that cause
replication and proliferation of cancer cells, re-establishes
pathways for apoptosis, or programmed cell death, in cancer cells,
and modulates the immune response against cancer cells. Oncoprex
has also been shown to block mechanisms that create drug
resistance. For more information, please visit the company’s web
site at www.genprex.com or follow Genprex on Twitter, Facebook and
LinkedIn.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are “forward-looking statements”
within the meaning of the Private Securities Litigation Reform Act
of 1995. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Such
statements include, but are not limited to, statements regarding
the effects of Oncoprex, or Oncoprex in combination with
immunotherapies, and Oncoprex combined with immunotherapies and
chemotherapies, on cancer. Risks that contribute to the uncertain
nature of the forward-looking statements include risks relating to
the effects of Oncoprex, alone and in combination with
immunotherapies and chemotherapies. Other risks and uncertainties
associated with Genprex and its lead product candidate Oncoprex are
described more fully under the caption “Risk Factors” and elsewhere
in our filings and reports with the United States Securities and
Exchange Commission. All forward-looking statements contained in
this press release speak only as of the date on which they were
made. We undertake no obligation to update such statements to
reflect events that occur or circumstances that exist after the
date on which they were made.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200106005059/en/
Genprex, Inc. (877) 774-GNPX (4679)
Investor Relations GNPX Investor Relations (877) 774-GNPX
(4679) ext. #2 investors@genprex.com
Media Contact Genprex Media Relations Kalyn Dabbs (877)
774-GNPX (4679) ext. #3 media@genprex.com
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Apr 2023 to Apr 2024